Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136275 · ClinicalTrials.gov registry record · Phase 1
CAR-37 T Cells in Hematologic Malignancies
A Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04136275 is a Phase 1 study that has completed, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 6 participants.
The verdict
NCT04136275, a Phase 1 study, has completed, sponsored by Marcela V. Maus, M.D.,Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. \- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment
Interventions
- BIOLOGICAL CAR-37 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136275
The ClinicalTrials.gov registry entry for NCT04136275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcela V. Maus, M.D.,Ph.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAR-37 T cells is the first listed.
NCT04136275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04136275 about?
NCT04136275 is a clinical study titled "CAR-37 T Cells in Hematologic Malignancies". This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. \- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cel...
What is the current status of trial NCT04136275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-06-19. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04136275?
The interventions under investigation include: CAR-37 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04136275?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.